Skip to main content

Table 3 Baseline phenotype and treatments of patients deceased or alive over the follow up

From: Phenotyping individuals with newly-diagnosed type 2 diabetes at risk for all-cause mortality: a single centre observational, prospective study

 

Deceased

36 (12.8%)

Alive

253 (87.2%)

p value

Age (years)

72.8 ± 9.0

61.9 ± 11.3

< 0.0001

Sex (n; %)

F 14 (38.9%)

M 22 (61.1%)

F 117 (46.2%)

M 136 (53.8%)

ns

BMI (kg/m2)

30.0 ± 5.8

30.6 ± 6.0

ns

SBP (mmHg)

145.6 ± 19.8

140.3 ± 19.7

ns

DBP (mmHg)

84.8 ± 11.3

82.8 ± 11.0

ns

Fasting glucose (mg/dL)

156 ± 50

158 ± 59

ns

Hb1Ac (%)

7.9 ± 1.3

7.6 ± 1.8

ns

Patients with HbA1c > 8% (n; %)

15; 45.5

58; 25.5

0.0174

Total cholesterol (mg/dL)

196 ± 40

203 ± 44

ns

HDL-cholesterol (mg/dL)

51 ± 14

48 ± 16

ns

LDL-cholesterol (mg/dL)

122 ± 53

122 ± 41

ns

Triglycerides (mg/dL)

136 ± 75

173 ± 108

ns

ALT (IU/L)

25 ± 12

33 ± 23

ns

AST (IU/L)

21 ± 7

25 ± 13

ns

γGT (IU/L)

44 ± 28

51 ± 62

ns

Serum creatinine (mg/dL)

1.06 ± 0.6

0.93 ± 0.37

ns

eGFR CKD-EPI (mL/min/1.73 m2)

70.6 ± 19.2

81.0 ± 20.0

0.0256

eGFR < 60 mL/min/1.73 m2 (n; %)

8; 22.2

30; 11.9

ns

Uric acid (mg/dL)

4.9 ± 1.1

6.2 ± 0.2

0.0291

Diabetic retinopathy (n; %)

1; 2.8

6; 2.4

ns

Previous CV disease (n; %)

6; 16.7

38; 15.0

ns

Heart failure (n; %)

4; 11.1

15; 5.9

ns

Atrial fibrillation (n; %)

6; 16.7

17; 6.7

0.0067

Any cancer (n; %)

10; 27.8

40; 15.8

ns

No treatment (n; %)

16; 44.4

139; 54.9

ns

Metformin (n; %)

12; 33.3

72; 28.5

ns

Secretagogues (n; %)

8; 22.2

42; 16.6

ns

Anti-hypertensive treatment (n; %)

23; 63.9

156; 61.6

ns

Statins (n; %)

14; 38.9

74; 29.2

ns